In recent years, the clinician has a more diverse approach to immunosuppression. Now, for many conditions, such as solid organ transplantation or treatment of some autoimmune diseases, the consequences of immunosuppression becomes a greater risk than organ failure from immune-mediated disease. Some of the consequences of immunosuppression can be prevented by prophylaxis, immunisation, surveillance and pharmacological intervention. Infections and malignancy are major causes of morbidity and mortality in the immunosuppressed. Screening for evidence of latent infection and immunisation prior to introduction of immunosuppression (where possible and appropriate) will help reduce the risk of infection. Surveillance for those cancers that are increased in association with immunosuppression (especially skin cancers, melanoma, anal canal, Kaposi, post-transplant lymphoproliferative disease) will allow early detection and intervention and, where appropriate, alteration of agent.

近年来，临床医生对免疫抑制采用了更加多样化的方法。现在，对于许多情况，例如实体器官移植或某些自身免疫性疾病的治疗，免疫抑制的后果比免疫介导的疾病导致的器官衰竭风险更大。免疫抑制的一些后果可以通过预防、免疫、监测和药物干预来预防。感染和恶性肿瘤是免疫抑制患者发病率和死亡率的主要原因。在引入免疫抑制之前（在可能和适当的情况下）筛查潜伏感染和免疫接种的证据将有助于降低感染风险。监测那些与免疫抑制相关的癌症（尤其是皮肤癌、黑色素瘤、肛管癌、卡波西癌、